1. In Vivo

The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

 
• By Anju Ghangurde

Supply chain expert outlines to In Vivo how pharma can create resilient and secure supply chains and some benefits of localization.

Strong Chain
• Source: Shutterstock

Pharmaceutical companies should use digital technologies to immunize their supply chain networks against threats like the coronavirus pandemic while they are still brewing on the horizon, much as a certain species of bird native to a hurricane-prone region of the US somehow knows to take off long before the high winds arrive, a leading supply chain expert recently suggested.

Robert Handfield, executive director of the Supply Chain Resource Cooperative and professor of supply chain management at North Carolina State...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing Focus

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.